Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -5.23%37 Net Debt Paydown Yield % is 9.79% as of Jul. 26, 2026, which is 331% above its 10-year median of 2.27. GuruFocus rates STU:FLB with a GF Score™ of 37/100 and a GF Value™ of €0.45 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 768 Medical Devices & Instruments companies, Standard BioTools ranks better than 92.71% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Standard BioTools's Net Debt Paydown Yield % was 9.79%.
Standard BioTools (STU:FLB) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Standard BioTools Net Debt Paydown Yield % Related Terms
Standard BioTools Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Standard BioTools's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 9.79% mean?
Standard BioTools (STU:FLB) has a Net Debt Paydown Yield % of 9.79% as of Jul. 26, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Standard BioTools and its competitors. This is 331% above median its historical median of 2.27. According to the industry distribution chart, Standard BioTools ranks #56 out of 768 companies in the Medical Devices & Instruments industry, placing it in the top 7.3%.
Is Standard BioTools' Net Debt Paydown Yield % too high?
Standard BioTools' current Net Debt Paydown Yield % of 9.79% is 331% above median its 10-year median of 2.27. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. Standard BioTools' value of 9.79% is 97800% above this industry median. Based on the distribution chart, Standard BioTools ranks #56 out of 768 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Net Debt Paydown Yield % compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #56 out of 768 companies for Net Debt Paydown Yield %. This places Standard BioTools in the top 7% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.01. Standard BioTools' value of 9.79% is 97800% above this benchmark. While the company's 10-year median is 2.27 vs. the industry median of 0.01, Standard BioTools has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Net Debt Paydown Yield % of 9.79% is 97800% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Net Debt Paydown Yield % is 9.79%, which is 331% above median its own 10-year median of 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.45, compared to a current price of €0.73 — trading 61.1% above its estimated fair value. The current Net Debt Paydown Yield % is 9.79%, which is 331% above median its 10-year median of 2.27 and 97800% above the Medical Devices & Instruments industry median of 0.01. Standard BioTools' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Net Debt Paydown Yield % is 9.79% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.73 is trading 61.1% above its estimated GF Value™ of €0.45.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Net Debt Paydown Yield %: 9.79% (331% above median its 10-year median of 2.27)
GF Value™: €0.45 vs. price of €0.73 (61.1% above fair value)
Industry Position: 97800% above the Medical Devices & Instruments median (#56 of 768)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
37GF Score
Get the complete analysis for STU:FLB
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
